Cancer Research | TROP2 as a Therapeutic Vulnerability Target Driven by the IFN-TRIM22-NF-κB Axis Following KRAS-MAPK Inhibition

This study reveals the molecular mechanism by which prolonged KRAS-MAPK inhibition induces interferon signaling and EMT transition, providing a novel TROP2-based combination therapy strategy to overcome drug resistance in pancreatic cancer, with direct implications for the design of preclinical models.

 

Literature Overview

The study, titled 'Prolonged KRAS-MAPK Inhibition Induces Interferon Signaling that Promotes Cell State Transition and Confers Therapeutic Vulnerabilities,' published in the journal Cancer Research, systematically investigates how prolonged use of KRAS-MAPK pathway inhibitors in pancreatic ductal adenocarcinoma (PDAC) unexpectedly activates interferon (IFN) signaling, thereby driving cell state transition toward a mesenchymal-like (EMT) phenotype and inducing acquired resistance. Using clinical samples, cell models, and animal experiments, the study identifies the TRIM22–NF-κB signaling axis as a key mediator of resistance and ultimately proposes TROP2-targeted antibody-drug conjugates (ADCs) as a potential strategy to overcome resistance. The research not only elucidates the transcriptional plasticity underlying resistance but also provides new therapeutic targets for clinical intervention.

Background Knowledge

Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy, long limited by the lack of effective targeted therapies. Although KRAS mutations occur in over 90% of PDAC cases and recent breakthroughs have been made with KRASG12C inhibitors, rapid development of resistance limits their efficacy. Resistance mechanisms include secondary mutations and cell state transitions, particularly toward basal-like or mesenchymal-like (EMT) states, which are closely associated with resistance to chemotherapy and targeted therapies. Currently, there remains a lack of systematic understanding of the upstream drivers of cell state transitions induced by KRAS inhibitor resistance. The study’s central question is: why does prolonged inhibition of the KRAS-MAPK pathway promote a more aggressive cell state? The authors hypothesize the existence of adaptive feedback signaling and use transcriptomic analysis to explore resistance-related pathways, ultimately focusing on the regulatory roles of IFN signaling and the E3 ubiquitin ligase TRIM22, revealing a novel IFN–TRIM22–NF-κB axis.

 

 

Research Methods and Experiments

The authors analyzed tumor biopsy samples from PDAC patients before and after treatment with the ERK inhibitor ulixertinib in a phase Ib clinical trial using bulk RNA-seq, revealing significant upregulation of IFN, NF-κB, and EMT-related signaling pathways following prolonged KRAS-MAPK inhibition. To mimic clinical resistance, the authors treated multiple early-passage patient-derived PDAC cell lines with ulixertinib or KRAS inhibitors (e.g., MRTX1133) for two weeks to establish resistant cell models (ERKi-R or KRASi-R). These resistant cells exhibited classic EMT morphology and molecular features, such as downregulation of E-cadherin, upregulation of vimentin, and enhanced migratory and invasive capabilities. Using gene co-expression network analysis (GeneRep–nSCORE), the authors identified TRIM22 as a key regulatory node. In multiple animal models, including xenografts and genetically engineered mouse models (KPPC), prolonged use of ERK or KRAS inhibitors induced TRIM22 and its homolog expression, accompanied by EMT and IFN signaling activation.

Key Conclusions and Perspectives

• Prolonged KRAS-MAPK inhibition induces IFN signaling activation, which subsequently upregulates TRIM22 expression via transcription factors IRF1 and IRF9, suggesting that IFN feedback is an adaptive response to resistance, offering important insights into experimental approaches for studying resistance mechanisms
• TRIM22, as an E3 ubiquitin ligase, promotes proteasomal degradation of IκBα, leading to sustained activation of the NF-κB pathway, which drives EMT programs and basal-like cell states, indicating that TRIM22 is a critical molecular link between MAPK inhibition and NF-κB activation, providing a novel node for targeting resistance pathways
• NF-κB activation further upregulates its target gene TROP2, which is highly expressed in basal-like PDAC, suggesting that TROP2 is a therapeutically exploitable vulnerability acquired post-resistance and an ideal target for ADC therapy
• Combining the TROP2-targeted antibody-drug conjugate sacituzumab govitecan with KRAS or ERK inhibitors significantly suppresses PDAC xenograft tumor growth, demonstrating that a rational strategy to overcome resistance is 'induce then target,' with direct implications for clinical combination therapy design

Research Significance and Prospects

This study challenges the traditional notion that 'continuous KRAS inhibition can control tumors' by revealing that prolonged targeted therapy can reshape tumor cell states and induce more aggressive phenotypes. From a drug development perspective, it proposes a 'synthetic lethality' therapeutic strategy: using KRAS inhibitors to 'induce' TROP2 expression, then using ADCs to 'eliminate' resistant clones. This provides a theoretical foundation for developing dynamic combination therapies. In terms of clinical monitoring, dynamic changes in TROP2 during treatment could serve as a biomarker for early detection of EMT transition and resistance. Regarding disease modeling, the study emphasizes the need to establish resistance models with long-term drug exposure to more accurately simulate clinical resistance processes, avoiding reliance solely on short-term drug sensitivity assays.

 

 

Conclusion

This study systematically elucidates a novel mechanism by which pancreatic cancer undergoes EMT transition and develops resistance through the IFN–TRIM22–NF-κB axis under prolonged KRAS-MAPK inhibition, redefining traditional 'resistance' as a targetable 'therapeutic vulnerability.' TRIM22 acts as a signaling hub linking MAPK inhibition to NF-κB activation, while its downstream effector TROP2 emerges as a clinically actionable target. The combination strategy of KRAS inhibitors with TROP2-ADCs represents a paradigm shift from 'passively responding to resistance' to 'actively inducing and eliminating resistant clones.' This discovery not only deepens our understanding of adaptive resistance in PDAC but also provides a directly translatable therapeutic approach, laying the foundation for improving patient outcomes. Future studies should explore the generalizability of this axis in other KRAS-mutant tumors and assess the clinical utility of monitoring dynamic TROP2 expression to enable precise intervention strategies.

 

Ashenafi Bulle, Yali Chen, Huaping Li, David D Tran, and Kian-Huat Lim. Prolonged KRAS-MAPK Inhibition Induces Interferon Signaling that Promotes Cell State Transition and Confers Therapeutic Vulnerabilities. Cancer research.